LIFESTANCE HEALTH GROUP INC (LFST)
Health Care · healthcare services · NASDAQ
LifeStance Health is a mental healthcare platform providing accessible, integrated outpatient behavioral health services through both in-person and virtual channels.
What LIFESTANCE HEALTH GROUP INC does
LifeStance Health Group, Inc. operates a mental healthcare platform that provides in-person and virtual outpatient care. The company partners with clinicians and health systems to offer services including psychiatry, psychology, and therapy, focusing on expanding patient access to behavioral health through a network of centers.
Themes: behavioral health, telehealth, mental health services
Fundamentals
- Price$12.22 as of 2026-10-20 close
- Market cap$4.7B as of 2026-07-29 (share count; price 2026-10-20)
- 1-year return+136.8% 2025-10-20 close $5.16 → 2026-10-20 close $12.22
- P/E94.00 as of 2026-10-20
- Net margin+0.7% FY2025, SEC XBRL
- ROE+0.6% FY2025, SEC XBRL
- ROIC+1.2% NOPAT / (debt + equity - cash), average capital — 10-K FY2025 (year ended 2025-12-31)
- Debt / equity0.19 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Revenue growth (YoY)+13.8% FY2025, SEC XBRL
- Revenue CAGR (3y)+18.3% SEC XBRL
- Beta0.73 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How LFST compares in its sector
- price-to-earnings ratiotop 10% 181 covered Health Care peers, as of 2026-10-20
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
LFST is not currently in any published Top 10 list. Its scores are below.
Top 10 score
50.6 #666 of 1,265 scored · #92 of 146 in Health Care
Trend 80th (over the past 12 months this stock beat the market by 122.3 percentage points) and growth 75th (3-year revenue CAGR 18.3%, revenue growth year over year 13.9%); weakest is profitability (18th, return on equity 0.6%, operating margin 1.7%).
Scores as of 20 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Operating cash flow | Capex |
|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $435M | $31M | $24M | $100M† | $12M† |
| Q1 FY2026 2026-03-31 | $403M | $22M | $14M | $33M | $11M |
| Q4 FY2025 2025-12-31 | $382M† | $18M† | $12M† | $58M† | $11M† |
| Q3 FY2025 2025-09-30 | $364M | $7M | $1M | $27M† | $10M† |
| Q2 FY2025 2025-06-30 | $345M | -$3M | -$4M | $64M† | $8M† |
| Q1 FY2025 2025-03-31 | $333M | $2M | $709000 | -$3M | $7M |
| Q4 FY2024 2024-12-31 | $325M† | $1M† | -$7M† | $62M† | $6M† |
| Q3 FY2024 2024-09-30 | $313M | $47000 | $709000 | $23M† | $5M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$226M
- Total debt$273M borrowings only; leases excluded
- Net debt$48M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How LIFESTANCE HEALTH GROUP INC looks technically
LIFESTANCE HEALTH GROUP INC (LFST) is trading 34.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 216 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 3 trading days ago (its momentum flipped negative). It made a new 20-day low about 3 trading days ago. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move. Trading volume is unusually light — only about 40% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 34.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +34.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $12.37 | $12.37 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $9.09 | $9.09 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 12.68. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 216 trading days ago — a "golden cross", a bullish long-term signal | 216 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend) | 13.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30) | 50.6 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($11.47 to $12.68) — its "stochastic" reading is 62 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 62.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 3 trading days ago (its momentum flipped negative) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $13.56 | $13.56 |
|---|---|---|
| From the 52-week high | it is 9.9% below its 52-week high (its highest price of the past year) | -9.9% |
| Above the 52-week low | it is 156.2% above its 52-week low (its lowest price of the past year) | +156.2% |
| Below the 52-week high | it is 9.9% below its highest point of the past year | 9.9% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 27 trading days ago | 27 sessions |
| All-time high | its highest closing price on record is $29.81 (set on 2021-07-07) | $29.81 |
| Given back of the 52-week move | over the past year its closes ranged ($4.81 to $13.38), and it has given back only a small part of its rise from last year’s low — 14% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $7.81 to $8.08. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 13.5% |
| From the all-time high | it is 59.0% below its all-time high | -59.0% |
| Nearest price level | it is trading 3.1% above a support level at $11.84 — a price it turned at twice since 2026-07-20, most recently on 2026-08-25. Since 2024-10-21 it has 14 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -3.1% |
| All-time low | its lowest closing price on record is $3.74 (set on 2025-08-01) | $3.74 |
| Above the all-time low | it is 226.7% above its all-time low | +226.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move | 1st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4196 between its high and its low — about 3.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4196 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $11.59 and $12.57 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $11.59 – $12.08 – $12.57 |
| Typical daily range (% of price) | its price moves about 3.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.4% |
| Stretch from the 200-day average | it is trading 7.5 daily ranges above its 200-day average price (34.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 40% of its 30-day average | 0.40× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
|---|---|---|
| Since a bearish engulfing | 5 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 5 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 1.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.4% |
|---|---|---|
| Gap filled | a 2.8% gap up opened on 2026-08-19 has been "filled" 40 sessions ago — price traded back through the level the gap left behind, and it took 3 sessions to close | 40 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +4.09% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 3.8 percentage points (the stock lost 2.8% while the market gained 1.0%) | -3.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 4.1 percentage points (the stock gained 7.8% while the market gained 3.6%) | +4.1% |
| vs market, 6 months | over the past 6 months this stock beat the market by 68.1 percentage points (the stock gained 76.6% while the market gained 8.5%) | +68.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 122.3 percentage points (the stock gained 136.8% while the market gained 14.6%) | +122.3% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is moderate, spanning 5.4% of the share price. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 28% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $9.56 — a volume-weighted average of daily closes over 200 sessions, not a true tick-by-tick VWAP. | +27.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $12.29 — a volume-weighted average of daily closes over 53 sessions, not a true tick-by-tick VWAP. | -0.6% |
Price levels it has turned at before
LFST last closed at $12.22 on 2026-10-20. Since 2024-10-21 it has turned at 14 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $11.84 | Support | 3.1% below the last close | turned there twice · 2026-07-20 to 2026-08-25 |
| $11.54 | Support | 5.5% below the last close | turned there twice · 2026-07-02 to 2026-10-02 |
| $8.21 | Support | 32.8% below the last close | turned there four times · 2025-01-28 to 2026-02-25 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $12.68.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $9.30 and $10.59 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $12.68.
This reading has stood for 1 trading day, since 2026-10-20.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading below the 50-day moving average · Broke down to a new 20-day low · MACD just crossed bearish (12/26/9) · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · bollinger bands · volume and relative volume
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.55 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$14.40 range $12.00 – $18.00; median $15.00
Analyst estimates, as of 2026-10-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for LFST
- Consensus EPS estimate$0.08388 next reporting period, as of 2026-10-17
- Estimate change, 30 days-$0.016 from $0.09988, on 2026-09-12, 35-day window
- Readings revised upward0% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["dependence on third-party payor reimbursement rates","reliance on ability to recruit and retain clinicians","risks associated with managing growth and regulatory compliance in a heavily regulated industry"]
What changed in the latest 10-Q
AI-assisted comparison of LFST's 10-Q filed 2026-08-06 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
- Reworded:
- The newer filing (2026-08-06) states the company employed 8,542 licensed mental health clinicians as of June 30, 2026, whereas the older filing (2026-05-07) stated 8,349 as of March 31, 2026.
- The newer filing (2026-08-06) refers to 'our current base of 8,542 clinicians employed through our subsidiaries and supported practices, as of June 30, 2026', whereas the older filing (2026-05-07) referred to 'our current base of 8,349 clinicians employed through our subsidiaries and supported practices, as of March 31, 2026'.
- Notes:
- The provided texts appear truncated at the end of both versions, so changes beyond the last visible line could not be assessed.
- Only the section text provided was compared; other portions of the MD&A were not included.
Risk Factors
- Added:
- Newer filing (2026-08-06) adds disclosure that during the fiscal quarter ended June 30, 2026, two directors or officers entered into, modified, or terminated Rule 10b5-1 plans or non-Rule 10b5-1 trading arrangements.
- Newer filing (2026-08-06) adds a specific disclosure that Lisa Miller, Chief Operating Officer, entered into a Rule 10b5-1 trading plan on May 7, 2026, to sell up to 77,297 shares between August 6, 2026 and February 5, 2027.
- Removed:
- Older filing (2026-05-07) includes an exhibit index (Item 6) listing certifications for the Principal Executive Officer and Principal Financial Officer; this exhibit index is not present in the newer filing text.
- Reworded:
- Newer filing (2026-08-06) updates the beneficial ownership percentage of the Principal Stockholders from approximately 43.6% as of March 31, 2026 in the older filing to approximately 35.4% as of June 30, 2026.
- Newer filing (2026-08-06) updates the stock repurchase table period from the three months ended March 31, 2026 to the three months ended June 30, 2026, with corresponding changes in monthly rows, shares purchased, average price, and remaining authorization amounts.
- Older filing (2026-05-07) states that during the fiscal quarter ended March 31, 2026, none of the directors or officers entered into, modified, or terminated such trading arrangements; the newer filing changes this to state that two directors or officers did so during the fiscal quarter ended June 30, 2026.
- Notes:
- The newer filing text appears truncated at the end of the exhibit list in the older filing and at the end of Item 5 in the newer filing, so a full comparison of exhibit items and the complete Item 5 disclosure may not be possible.
- The section labeled 'Risk Factors' in both filings also contains subsequent items (Unregistered Sales of Equity Securities, Defaults Upon Senior Securities, Mine Safety Disclosures, Other Information, Exhibits), which were compared as part of the provided texts.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 8 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 90 days · read to 2026-10-160 buys · 8 sells ($379M) — 5 selling insiders
- Last 180 days · read to 2026-10-160 buys · 17 sells ($669M) — 8 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-11. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about LFST's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding LFST as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 104,910,518
- Reported value $1,123,591,644
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about LFST's institutional holders → See what each manager we track holds →
Short interest (FINRA)
LFST had 15,508,383 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
LFST had 4.06% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.55 days to cover at the same settlement.
- Reported short interest (shares) 15,508,383
- Short interest (% of shares outstanding) 4.06%
- Prior settlement (shares) 16,260,201
- Reported change -4.62%
- Days to cover (reported) 2.55
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Talkspace (TALK)
- Hims & Hers Health (HIMS)
- Teladoc Health (TDOC)
- Acadia Healthcare (ACHC)
- Universal Health Services (UHS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare LFST vs…
LIFESTANCE HEALTH GROUP INC is found in…
Frequently asked questions
What does LIFESTANCE HEALTH GROUP INC (LFST) do?
LifeStance Health Group, Inc. operates a mental healthcare platform that provides in-person and virtual outpatient care. The company partners with clinicians and health systems to offer services including psychiatry, psychology, and therapy, focusing on expanding patient access to behavioral health through a network of centers.
What sector is LIFESTANCE HEALTH GROUP INC (LFST) in?
LIFESTANCE HEALTH GROUP INC (LFST) is classified in the Health Care sector. Its industry is healthcare services. It trades on NASDAQ.
Who are LIFESTANCE HEALTH GROUP INC's (LFST) competitors?
Notable peers of LIFESTANCE HEALTH GROUP INC (LFST) include Talkspace, Hims & Hers Health, Teladoc Health, Acadia Healthcare and Universal Health Services. This peer set is informational only — not financial advice.
Is LIFESTANCE HEALTH GROUP INC (LFST) overbought or oversold right now?
LIFESTANCE HEALTH GROUP INC (LFST) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 51, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on LFST come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.